IL1B and lattice corneal dystrophy type I: Our network pharmacology analysis identified TNF-α, IL-6, and IL-1β as core targets, which was experimentally confirmed through dramatic 4.18-6.41-fold reductions in these inflammatory mediators following LCD treatment.